Company: ATRA
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-059322
Chunk: 40

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 40
---
 “group” of which such holder is a member, would beneficially own a number of shares of the Common Stock in excess of 9.99% of the shares of the Company’s common stock then issued and outstanding, which percentage may be changed at a holder’s election upon 61 days’ notice to the Company.

The indicated ownership is based solely on a Schedule 13G/A filed with the SEC by the reporting person on November 14, 2024. The Schedule 13G provides information as of September 30, 2024 and, consequently, the beneficial ownership of the reporting person may have changed between September 30, 2024 and March 14, 2025. As of September 30, 2024, EcoR1 Capital, LLC (“EcoR1 Capital”) and Oleg Nodelman (“Nodelman”) held shared voting power and shared dispositive power over 493,463 of such shares and EcoR1 Capital Fund Qualified, L.P. held shared voting power and shared dispositive power over 465,559 of such shares. The address of each of the foregoing entities is 357 Tehama Street #3, San Francisco, CA 94103.

Consists of 38,392 shares held directly by Dr. Touchon and 31,853 shares pursuant to options exercisable within 60 days of March 14, 2025.

Consists of 4,360 shares held directly by Mr. Fust and 6,840 shares pursuant to options exercisable within 60 days of March 14, 2025.

Consists of 19,184 shares held directly by Dr. Gallagher and 6,840 shares pursuant to options exercisable within 60 days of March 14, 2025.

Consists of 8,360 shares held directly by Mr. Heiden and 6,840 shares pursuant to options exercisable within 60 days of March 14, 2025.

Consists of 8,837 shares held directly by Ms. Henrich and 8,189 shares pursuant to options exercisable within 60 days of March 14, 2025.

Consists of 10,505 shares held directly by Mr. Hyllengren and 13,134 shares pursuant to options exercisable within 60 days of March 14, 2025. In connection with Mr. Hyllengren's departure from the Company, he relinquished all of his vested and unvested stock options.

Cons